Status:
COMPLETED
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
Brief Summary
The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-c...
Eligibility Criteria
Inclusion
- Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
- Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra).
- Have received at least one dose of atezolizumab as per local label and clinical practice.
Exclusion
- Contraindicated atezolizumab therapy
Key Trial Info
Start Date :
February 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03330886
Start Date
February 9 2018
End Date
March 2 2019
Last Update
March 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Productos Roche S.A. Quimica e Industrial, División Farmacéutica
Buenos Aires, Argentina, B1610BAL